Mobile Site ›
Print Friendly View

Test ID: NMDCC    
NMDA-Receptor Antibody by CBA, Spinal Fluid

Secondary ID A test code used for billing and in test definitions created prior to November 2011

61513

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluating new onset encephalopathy (noninfectious or metabolic) comprising 1 or more of the following: confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, seizures, or hypoventilation

 

Evaluating limbic encephalitis

 

Directing a focused search for cancer

 

Investigating encephalopathy appearing in the course or wake of cancer therapy, and not explainable by metastasis or drug effect 

Method Name A short description of the method used to perform the test

Cell-binding assay (CBA) detects IgG specific for NMDA-R (N-Methyl-D-aspartate receptor) by indirect immunofluorescence (IFA)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

NMDA-R Ab CBA, CSF

Aliases Lists additional common names for a test, as an aid in searching

Anti-NMDA
N-Methyl D-Aspartate Ab
NMDA Receptor Ab